HOME >> MEDICINE >> NEWS
Some breast cancer patients may benefit from endocrine therapy alone

SAN ANTONIO -- The estrogen receptor status of breast cancer may help to predict which patients will benefit from chemotherapy treatment, say researchers at The University of Texas M. D. Anderson Cancer Center.

Their study, presented at the San Antonio Breast Cancer Symposium, could change the way breast cancer is treated in the future. Now, patients routinely receive chemotherapy as their first treatment, followed by surgery. Patients with estrogen-positive tumors --tumors that use estrogen to fuel their growth -- may then receive endocrine therapies that block the estrogen action or production, or interfere with the hormonal pathways.

This study suggests patients with estrogen-positive cancer may benefit more from an initial treatment of endocrine therapies rather than chemotherapy.

"We hope this study will help to direct the best treatment for patients," says the study's author, Aman Buzdar, M.D., professor in the Department of Breast Medical Oncology at M. D. Anderson. "In the future, we may be able to identify patients who will do well with endocrine therapies alone."

Buzdar and a team of researchers looked at tumor samples of 1,018 patients followed at the center since 1975 in which the estrogen receptor status was known. All patients received chemotherapy and surgery.

The investigators looked for the evidence of a complete "pathological response" to treatment (there was no invasive cancer left either in the breast or in the lymph nodes), and separated the results by estrogen receptor status. They found that more than 20 percent of patients with estrogen-negative breast cancer had a complete pathologic response compared with five percent in estrogen-positive cancer.

"It didn't matter what kind of chemotherapy was used, there was more benefit observed in patients with estrogen receptor-negative cancers," says Buzdar. "Even though a significant number of estrogen-positive patients had clinical regression in thei
'"/>


4-Dec-2003


Page: 1 2

Related medicine news :

1. International breast cancer prevention study launches in the United States and Canada
2. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
3. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
4. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
5. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women
6. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
7. Postmenopausal breast cancer survivors at increased risk for bone fractures
8. Nursing mothers having surgery -- How long a wait to breastfeed safely?
9. Researchers close in on breast cancer vaccine
10. Simple question from your doctor can help identify your risk for breast cancer
11. Non-invasive and invasive breast cancers share the same genetic mutations

Post Your Comments:
(Date:7/21/2014)... PowerObjects, a professional services firm ... add-ons for Microsoft Dynamics CRM, has joined the ... group of the most strategic Microsoft Dynamics partners ... rank them in the highest echelon of the ... the Microsoft Dynamics Inner Circle have performed to ...
(Date:7/21/2014)... have a clot in their legs and are ... medication or undergo a minimally-invasive catheter-based clot removal ... difference in death rates between the two treatments, ... catheter procedure, according to a study by Temple ... a review of more than 90,000 cases nationwide., ...
(Date:7/21/2014)... The "viral reservoir" in which HIV can lie dormant ... earlier than previously thought, new animal research indicates. ... eradicate the AIDS-causing virus, said Harvard researchers working with ... presence of the viral reservoir remains the most significant ... HIV, known as HIV-1. "We found that the ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Western ... “Great College to Work For” by the Chronicle ... and also made the Honor Roll for the ... categories: Collaborative Governance, Compensation and Benefits, Confidence in ... Respect & Appreciation. , “Western University of Health ...
(Date:7/21/2014)... A new study suggests that potential help in lowering ... refrigerator. The study found that regular intake of ... supplements, may help ease the condition. Researchers looked ... probiotics and blood pressure. The studies involved a total ... pressure. People who consumed probiotics had an average ...
Breaking Medicine News(10 mins):Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
Cached News: